Cargando…

Fatty acids metabolism affects the therapeutic effect of anti-PD-1/PD-L1 in tumor immune microenvironment in clear cell renal cell carcinoma

BACKGROUND: Clear cell renal cell carcinoma (ccRCC) is a highly invasive and metastatic subtype of kidney malignancy and is correlated with metabolic reprogramming for adaptation to the tumor microenvironment comprising infiltrated immune cells and immunomodulatory molecules. The role of immune cell...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Hansen, Fu, Liangmin, Li, Pengju, Zhu, Jiangquan, Xu, Quanhui, Wang, Yinghan, Mumin, Mukhtar Adan, Zhou, Xinwei, Chen, Yuhang, Shu, Guannan, Yao, Gaosheng, Chen, Minyu, Lu, Jun, Zhang, Lizhen, Liu, YuJun, Zhao, Yiqi, Bao, Jiahao, Chen, Wei, Luo, Junhang, Li, Xiaofei, Chen, Zhenhua, Cao, Jiazheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10204332/ https://www.ncbi.nlm.nih.gov/pubmed/37221577 http://dx.doi.org/10.1186/s12967-023-04161-z

Ejemplares similares

Neoadjuvant and adjuvant chemotherapy share equivalent efficacy in improving overall survival and cancer-specific survival among muscle invasive bladder cancer patients who undergo radical cystectomy: a retrospective cohort study based on SEER database
por: Tan, Zhiping, et al.
Publicado: (2023)

Development and validation of a novel defined mutation classifier based on Lasso logistic regression for predicting the overall survival of immune checkpoint inhibitor therapy in renal cell carcinoma
por: Chen, Minyu, et al.
Publicado: (2023)

EHBP1L1 Drives Immune Evasion in Renal Cell Carcinoma through Binding and Stabilizing JAK1
por: Pan, Yihui, et al.
Publicado: (2023)

Development and external validation of the multichannel deep learning model based on unenhanced CT for differentiating fat-poor angiomyolipoma from renal cell carcinoma: a two-center retrospective study
por: Yao, Haohua, et al.
Publicado: (2023)

Hsa_circ_0057105 modulates a balance of epithelial‐mesenchymal transition and ferroptosis vulnerability in renal cell carcinoma
por: Cen, Junjie, et al.
Publicado: (2023)

Overexpression of TREM1 is Associated with the Immune-Suppressive Microenvironment and Unfavorable Prognosis in Pan-Cancer
por: Zhou, Xinwei, et al.
Publicado: (2023)

Identification of an Immune-Related Risk Signature Correlates With Immunophenotype and Predicts Anti-PD-L1 Efficacy of Urothelial Cancer
por: Li, Pengju, et al.
Publicado: (2021)

Crosstalk of necroptosis and pyroptosis defines tumor microenvironment characterization and predicts prognosis in clear cell renal carcinoma
por: Fu, Liangmin, et al.
Publicado: (2022)

Bladder cancer intrinsic LRFN2 drives anticancer immunotherapy resistance by attenuating CD8(+) T cell infiltration and functional transition
por: Yu, Anze, et al.
Publicado: (2023)

The impact of tumor size on the survival of patients with small renal masses: A population–based study
por: Tang, Yiming, et al.
Publicado: (2022)

The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer
por: Qu, Jingjing, et al.
Publicado: (2021)

M1-like TAMs are required for the efficacy of PD-L1/PD-1 blockades in gastric cancer
por: Zhao, Rui, et al.
Publicado: (2020)

Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
por: Yi, Ming, et al.
Publicado: (2018)

C4-arylation and domino C4-arylation/3,2-carbonyl migration of indoles by tuning Pd catalytic modes: Pd(i)–Pd(ii) catalysis vs. Pd(ii) catalysis
por: Cheng, Yaohang, et al.
Publicado: (2021)

Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy
por: Long, Yiru, et al.
Publicado: (2022)

Machine learning: an approach to preoperatively predict PD-1/PD-L1 expression and outcome in intrahepatic cholangiocarcinoma using MRI biomarkers
por: Zhang, Jun, et al.
Publicado: (2020)

Accumulation of dysfunctional tumor-infiltrating PD-1+ DCs links PD-1/PD-L1 blockade immunotherapeutic response in cervical cancer
por: Wang, Yu-meng, et al.
Publicado: (2022)

PD-L1 methylation restricts PD-L1/PD-1 interactions to control cancer immune surveillance
por: Huang, Changsheng, et al.
Publicado: (2023)

Drug response to PD-1/PD-L1 blockade: based on biomarkers
por: Chen, Qi, et al.
Publicado: (2018)

PD-1(+) mast cell enhanced by PD-1 blocking therapy associated with resistance to immunotherapy
por: Li, Jun, et al.
Publicado: (2022)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
por: Liu, Jinhua, et al.
Publicado: (2021)

Recent Advancements in the Mechanisms Underlying Resistance to PD-1/PD-L1 Blockade Immunotherapy
por: Yuan, Yu, et al.
Publicado: (2021)

PD-1/PD-L1 immune checkpoint inhibitors in neoadjuvant therapy for solid tumors (Review)
por: Tang, Quanying, et al.
Publicado: (2023)

Extracellular Vesicle-Mediated Transfer of LncRNA IGFL2-AS1 Confers Sunitinib Resistance in Renal Cell Carcinoma
por: Pan, Yihui, et al.
Publicado: (2023)

High‐affinity PD‐1 molecules deliver improved interaction with PD‐L1 and PD‐L2
por: Li, Yanyan, et al.
Publicado: (2018)

Downregulation of the PD-1/PD-Ls pathway in peripheral cells correlates with asbestosis severity
por: Qiu, Meihua, et al.
Publicado: (2021)

Ocular adverse events in PD-1 and PD-L1 inhibitors
por: Young, LeAnne, et al.
Publicado: (2021)

Oncolytic virus and PD-1/PD-L1 blockade combination therapy
por: Chen, Chun-Yu, et al.
Publicado: (2018)

Case Report: Replacement of PD-1 inhibitors with PD-L1 inhibitors in the treatment of squamous non-small-cell lung carcinoma
por: Wu, Tong, et al.
Publicado: (2023)

Differential expressions of PD-1, PD-L1 and PD-L2 between primary and metastatic sites in renal cell carcinoma
por: Zhang, Xingming, et al.
Publicado: (2019)

PD-1/PD-L1 regulates Treg differentiation in pregnancy-induced hypertension
por: Jiang, Lai, et al.
Publicado: (2018)

The Diverse Function of PD-1/PD-L Pathway Beyond Cancer
por: Qin, Weiting, et al.
Publicado: (2019)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
por: Li, Qian, et al.
Publicado: (2022)

Core-shell Au@Pd nanoparticles with enhanced catalytic activity for oxygen reduction reaction via core-shell Au@Ag/Pd constructions
por: Chen, Dong, et al.
Publicado: (2015)

Antigen-Presenting Cell-Intrinsic PD-1 Neutralizes PD-L1 in cis to Attenuate PD-1 Signaling in T Cells
por: Zhao, Yunlong, et al.
Publicado: (2018)

Effect of CRISPR/Cas9-Edited PD-1/PD-L1 on Tumor Immunity and Immunotherapy
por: Xu, Yanxin, et al.
Publicado: (2022)

Association of PD-1 and PD-L1 Genetic Polymorphyisms with Type 1 Diabetes Susceptibility
por: Qian, Chenyue, et al.
Publicado: (2018)

Expression of PD-1, PD-L1 and PD-L2 is associated with differentiation status and histological type of endometrial cancer
por: Mo, Zhongfu, et al.
Publicado: (2016)

Bioinspired Pd-Cu Alloy Nanoparticles as Accept Agent for Dye Degradation Performances
por: Chen, Shiyue, et al.
Publicado: (2022)

Recent developments in PD-1/PD-L1 blockade research for gastroesophageal malignancies
por: Chen, Meng, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_eg7vr3vlhg0qaq8aephnir6pq5